VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS

VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ...
Healio

FDA grants fast track designation to vectorized antibody to treat ALS

The FDA has granted fast track designation to a vectorized antibody that targets RNA-binding proteins characteristic of ...
ALS News Today

First human trial begins in Europe for ALS, Parkinson’s drug NRG5051

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
Morningstar

QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener

QurAlis intends to advance QRL-101 into Phase 2 proof-of-concept clinical trials as a potentially best-in-class treatment for both DEE and ALS QurAlis Corporation (“QurAlis”), a clinical-stage ...
MarketWatch

Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS

The MarketWatch News Department was not involved in the creation of this content. SAN CARLOS, Calif., Jan. 6, 2026 /PRNewswire/ -- Aperture Therapeutics, a biotechnology company pioneering ...
Business Wire

Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced the ...
STAT

After Amylyx ALS trial failure, patients share disappointment and fear — but some hope

The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...
Morningstar

VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS

VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS ~ Designation enables an enhanced development ...
Yahoo Finance

QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener

QurAlis intends to advance QRL-101 into Phase 2 proof-of-concept clinical trials as a potentially best-in-class treatment for both DEE and ALS CAMBRIDGE, Mass., December 29, 2025--(BUSINESS ...